Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165007 · ClinicalTrials.gov registry record · Phase 1
Haploidentical Hematopoietic Stem Cell Transplantation
A Phase 1 study, sponsored by Catherine Bollard.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02165007 is a Phase 1 study that has completed, run by Catherine Bollard. The registered enrollment target is 7 participants.
The verdict
NCT02165007, a Phase 1 study, has completed, sponsored by Catherine Bollard.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia. The purpose of the study is to assess the safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell transplantation.
Interventions
- DRUG peripheral blood stem cell graft that are CD34+ selected
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-01 |
| Est. Completion | 2024-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02165007
The ClinicalTrials.gov registry entry for NCT02165007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catherine Bollard, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which peripheral blood stem cell graft that are CD34+ selected is the first listed.
NCT02165007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02165007 about?
NCT02165007 is a clinical study titled "Haploidentical Hematopoietic Stem Cell Transplantation". The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia. The purpose of the study is to assess the safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell transplantation.
What is the current status of trial NCT02165007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-01. Estimated completion is 2024-10.
What interventions are being tested in trial NCT02165007?
The interventions under investigation include: peripheral blood stem cell graft that are CD34+ selected (DRUG).
Who is sponsoring clinical trial NCT02165007?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.